Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform
13 juin 2019 06h55 HE
|
Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., June 13, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it has...
斯丹赛生物技术有限公司 Innovative Cellular Therapeutics 宣佈圓滿完成與 FDA 的臨床試驗審請前（Pre-IND）會議
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
中國上海和馬里蘭州羅克維爾, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司 (Innovative Cellu lar Therapeutics, ICT）是一間生物技術公司，主力開發治療癌症的細胞免疫療法。該公司在今天宣布與美國食品和藥物管理局（FDA）的臨床試驗審查前會議﹙研究性新藥﹚已圓滿結束。在會議上，FDA 就 ICT...
斯丹赛生物技术有限公司宣布圆满完成与FDA的新药临床试验申请前（Pre-IND）会议
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
中国上海及美国马里兰州罗克维尔, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司（Innovative Cellular...
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
SHANGHAI, China and ROCKVILLE, Md., April 09, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of...
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
19 mars 2019 08h00 HE
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it...
Pet Cancer Therapeutics Market to hit $359.4 Million by 2025: Global Market Insights, Inc.
15 mars 2019 03h04 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, March 15, 2019 (GLOBE NEWSWIRE) -- Australian pet cancer therapeutics market is forecast to grow at over 12.6% CAGR in given timeframe. High growth is due to growing...
Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members to Executive Leadership Team
06 mars 2019 17h00 HE
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced...
Ett nytt studieresultat med AroCell TK 210 ELISA vid prostatacancer har accepterats för publicering
25 févr. 2019 02h30 HE
|
AroCell AB
Studien med titeln “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions”,...
New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication
25 févr. 2019 02h30 HE
|
AroCell AB
The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous...
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
07 févr. 2019 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...